4D Molecular Therapeutics, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2021
4D Molecular Therapeutics, Inc. announced unaudited earnings results for the first quarter ended March 31, 2021. Total revenue was $2,000,000 as compared to $3,535,000 a year ago. Loss from operations was $16,312,000 as compared to $13,277,000 a year ago. Net loss and comprehensive loss was $16,406,000 as compared to $13,160,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted $0.61 against $2.54 a year ago.